从覆盖1.3亿肾病患者的全周期保险矩阵，到服务4.5亿慢肝人群的"惠肝保"，众惠相互通过深度定制产 品与普惠模式，让带病体、高风险群体不再是保障的"孤岛"，为多层次医疗保障体系建设提供了切实可 行的"众惠方案"。 政策破冰，实践先行 近期，国家医保局、国家卫生健康委联合印发的《支持创新药高质量发展的若干措施》（以下简称《若 干措施》）正式实施，标志着我国创新药保障体系进入"基本医保保基本、商保补充促创新"的双轨驱动 时代。 "治不起、管不好"是我国数亿慢性病患者的共同困境。面对基本医保覆盖有限、传统商保门槛过高的双 重挑战，保障体系亟须创新力量。以众惠财产相互保险社（以下简称"众惠相互"）为代表的相互保险机 构，凭借其独特的制度基因，正精准切入这一巨大空白。 可以说，众惠相互聚集慢性肾脏病患者"治不起、管不好"的痛点，一方面，精准锚定慢性病患者的核心 痛点，以覆盖全病程的深度定制产品，成功打破了传统商保对带病体的桎梏。 另一方面，不断完善健康管理服务内容，拓展服务领域和服务方式，为客户提供全方位、个性化的健康 保障解决方案，着力提升人民群众的获得感和满意度。 制度赋能，普惠创新 传统商业保险长期受困于风险控制 ...

Core Viewpoint - The conference hosted by Tsinghua University Wudaokou School of Finance focused on the theme of "New Industries, New Technologies, New Models, New Dynamics - Digital Finance Supporting High-Quality Development," highlighting the importance of digital finance in enhancing the quality of economic growth in China [1]. Group 1: Industry Trends - The Chinese commercial health insurance industry is undergoing profound changes, transitioning from a supplementary role to a complementary relationship with the basic medical insurance system, thereby participating deeply in the construction of a multi-tiered medical security system [2][4]. - The mutual insurance model is positioned as a crucial "adhesive" between social security and commercial insurance, aligning with the public welfare direction of China's healthcare reform [2]. Group 2: Market Dynamics - The medical insurance market is experiencing structural changes due to healthcare payment reforms, shifting the development logic from "supplementary" to "complementary," with commercial insurance focusing on differentiated areas such as outpatient drugs and mid-to-high-end services [4][5]. - The mutual insurance model's "co-construction, co-governance, and sharing" mechanism fills the gap between social security and traditional commercial insurance, creating a new type of security system through collaborative platforms and ecological synergy [5][6]. Group 3: Challenges and Innovations - The insurance industry faces a core dilemma of mismatched products and user needs, with traditional sales methods often leading to misunderstandings due to product complexity [7]. - The company is focusing on risk reduction for specific groups, such as potential liver disease patients, by developing innovative insurance products that enhance patient compliance and reduce economic burdens [6][7]. Group 4: Future Directions - The company aims to evolve medical health insurance from risk compensation to risk reduction, contributing to the "Healthy China 2030" initiative by leveraging technology for precise matching and continuous engagement with members [7].